M. V. Israpiyev

M. V. Israpiyev

Auto-generated profile, based on publicly available information

M. V. Israpiyev

Research Institute for Healthcare Organization and Medical Management

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2023 in Russian Sklifosovsky Journal "Emergency Medical Care"
Verified
Journal Article
Open access
PDF file
MIM. V. Israpiyev
M. V. Israpiyev
SNS. S. Niyazov
S. S. Niyazov
NBN. M. Bikbova
N. M. Bikbova
АРА. В. Редкобородый
А. В. Редкобородый
NRN. V. Rubtsov
N. V. Rubtsov
VVV. V. Vladimirov
V. V. Vladimirov
Clinical case. A patient after mitral valve replacement surgery for infective endocarditis was hospitalized with a new coronavirus infection. The examination revealed a left ventricular-right atrial communication. The complex treatment with a good clinical effect was performed at the N.V. Sklifosovsky Research Institute for Emergency Medicine. Conclusions In the context of a pandemic of a new coronavirus infection, patients with a new coronavirus infection who have undergone a history of heart surgery are subject to greater clinical vigilance regarding the development of postoperative complications, including rare ones.

24 September 2025 in Russian Sklifosovsky Journal "Emergency Medical Care"
Verified
Journal Article
Open access
PDF file
MKM. Sh. Khubutiya
M. Sh. Khubutiya
ATA. S. Tokarev
A. S. Tokarev
NRN. V. Rubtsov
N. V. Rubtsov
MIM. V. Israpiev
M. V. Israpiev
LKL. G. Khutsishvili
L. G. Khutsishvili
IAI. A. Argir
I. A. Argir
Chronic heart failure (CHF) is a progressive and irreversible syndrome that develops against the background of structural and functional disorders of the heart. It is accompanied by a decrease in cardiac output, pressure overload and a high level of hospitalizations, which makes CHF one of the key medical and social problems of our time. In recent decades, the prevalence of CHF has been steadily increasing, especially among the elderly population, which is associated with an increase in life expectancy and an improvement in the quality of medical care. According to forecasts, by 2050 the number of patients will increase by 50-60% compared to 2010.The terminal stage of CHF is characterized by an extremely unfavorable prognosis: survival does not exceed 25-30%. Heart transplantation (HT) remains the only radical treatment method that can significantly improve survival and quality of life. However, the shortage of donor organs and the growing number of patients necessitate the use of mechanical circulatory support (MCS) as a temporary or long-term alternative.MPC systems act as a “bridge” to transplantation, allowing for hemodynamic stabilization and organ function support before surgery. The most common short-term support technologies are extracorporeal membrane oxygenation (ECMO), intra-aortic balloon pump (IABP), and temporary axial pumps (Impella, TandemHeart). ECMO provides both respiratory and hemodynamic support, but is associated with a high risk of complications and relatively low survival. IABP is the most accessible method, improving coronary perfusion, but provides limited support. Impella devices demonstrate higher efficiency, unloading the left ventricle and improving systemic hemodynamics, while being characterized by fewer complications. TandemHeart provides a comparable effect, but requires a more complex installation technique.The choice of MPC method depends on the patient’s condition, the severity of multiorgan dysfunction, the availability of equipment, and the qualifications of the specialists. Current research confirms that a combination of different devices (e.g., ECMO and Impella) can improve outcomes.Thus, mechanical circulatory support occupies a central place in the treatment of terminal heart failure in conditions of limited donor resources, allowing to gain time before transplantation and reduce mortality on the waiting list.

30 January 2026 in Russian Sklifosovsky Journal "Emergency Medical Care"
Verified
Journal Article
Closed access
MKM. Sh. Khubutiya
M. Sh. Khubutiya
ATA. S. Tokarev
A. S. Tokarev
NRN. V. Rubtsov
N. V. Rubtsov
MIM. V. Israpiev
M. V. Israpiev
IKI. G. Khutsishvili
I. G. Khutsishvili
IAI. A. Argir
I. A. Argir
This article reviews modern technologies for durable mechanical circulatory support (dMCS) —implantable devices that replace or support cardiac function. The process of improving circulatory support devices has spanned several decades. We have evolved from bulky first-generation pulsatile pumps to compact and reliable non-pulsatile flow pumps. Today, these highly effective systems are used in 95% of cases. Modern devices can serve not only as a bridge to heart transplantation for patients awaiting a donor organ, but also as ongoing therapy for patients who are not eligible for a heart transplant. At the same time, trends toward improving the quality of medical care are also impacting the refinement of existing circulatory support techniques: minimally invasive devices for full and partial cardiac support are being developed; fully magnetically levitated centrifugal-flow left ventricular assist devices are becoming dominant; solutions for right ventricular and biventricular failure, including the total artificial heart, are emerging. Sputnik portable circulatory support devices and STREAM CARDIO systems have been developed and are being used in Russia. They are comparable in efficacy and safety to their foreign counterparts, and in some respects (for example, antithrombogenic coating) they are superior. Their main advantage is their significantly lower cost and accessibility for Russian patients, which is critically important given the shortage of donor organs and the high cost of imported systems. DMCS has become a life-saving and life-preserving standard practice in cardiac surgery. Given current demographic conditions, the growing proportion of patients with heart failure, and the chronic shortage of donor organs, further development and cost reduction of the aforementioned technologies is a strategic necessity for this country.